Praxis Precision Medicines, INC

Praxis Precision Medicines announces a research collaboration and license agreement with Remagine Labs to develop a transdermal patch for essential tremor treatment.

Praxis Precision Medicines announced an FDA review extension for relutrigine, pushing the target action date to December 27, 2026.

Praxis Precision Medicines stockholders re-elected three Class III directors and ratified the appointment of Ernst & Young LLP.

Praxis Precision Medicines announced its Phase 2/3 POWER1 study for vormatrigine in focal onset seizures did not meet its primary success measure, leading to a pause in enrollment for the POWER2 study.

Praxis Precision Medicines reported Q1 2026 financial results, highlighting FDA acceptance of two NDAs and positive clinical trial updates across its CNS pipeline, with substantial cash reserves extending runway into 2028.

Praxis Precision Medicines announced the FDA has accepted its New Drug Application for ulixacaltamide HCl for essential tremor.

Praxis Precision Medicines reports increased R&D spending and net loss in Q1 2026, but maintains a strong cash position and advances multiple drug candidates.

Praxis Precision Medicines reports significant clinical progress across its CNS pipeline, including positive Phase 3 results for ulixacaltamide and Breakthrough Therapy Designation for relutrigine, while extending its cash runway into 2028 with a recent $567 million public offering.

Praxis Precision Medicines reported a significant increase in net loss for Q2 2025 driven by expanded R&D, while extending its cash runway into 2028 and advancing multiple clinical programs.

Praxis Precision Medicines reports a net loss of $69.3 million for Q1 2025, focusing on advancing clinical trials and research efforts.

Praxis Precision Medicines reports a net loss of $51.9 million for the third quarter of 2024, while advancing its clinical programs and maintaining a strong cash position.

Praxis Precision Medicines reports a net loss of $72.2 million for the first half of 2024, while advancing its clinical programs and securing significant funding.

Praxis Precision Medicines announced positive Phase 3 clinical trial results for ulixacaltamide in Essential Tremor and relutrigine in SCN2A/SCN8A DEEs, alongside significant capital raises.

Praxis Precision Medicines details its 2024 financial performance and provides updates on its clinical-stage programs, including a futility recommendation for a Phase 3 Essential Tremor study.

Praxis Precision Medicines' 2023 10-K filing details financial losses, clinical trial advancements, and strategic plans for its CNS disorder therapies.

Praxis Precision Medicines CEO Marcio Souza reports a gift of common stock to a trust, impacting his beneficial ownership.

Jill DeSimone, a Director at Praxis Precision Medicines, Inc., reported transactions involving the sale of common stock and the acquisition of stock options on June 24, 2026.

Director Stuart Arbuckle acquired 1,371 restricted stock units and 648 stock options in Praxis Precision Medicines, Inc.

Director Jeffrey Chodakewitz was granted 1,371 restricted stock units and 648 stock options by Praxis Precision Medicines.

Director William D. Young was granted 1,371 restricted stock units and 648 stock options by Praxis Precision Medicines.

Director Jill DeSimone acquired 1,371 restricted stock units and 648 stock options in Praxis Precision Medicines, Inc.

Praxis Precision Medicines has filed a definitive proxy statement with the SEC.

Praxis Precision Medicines reports on a year of growth and execution, highlighting progress in advancing its pipeline of neurological disorder treatments and outlining key milestones for 2025 and beyond.

Praxis Precision Medicines has filed a definitive proxy statement with the SEC.

Praxis Precision Medicines is asking stockholders to approve an amendment to its 2020 Stock Option and Incentive Plan to increase the number of shares available for issuance.

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have filed a Schedule 13G, reporting a combined beneficial ownership of 8.9% in Praxis Precision Medicines, Inc.

FMR LLC has reported beneficial ownership of 7.7% of Praxis Precision Medicines Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.09% of Praxis Precision Medicines Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Praxis Precision Medicines Inc. following an internal realignment.

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly disclosed a 5% beneficial ownership stake in Praxis Precision Medicines, Inc. common stock.

Adage Capital Management, L.P. and its principals reported a 3.83% beneficial ownership stake in Praxis Precision Medicines, Inc. as of December 31, 2025.